Organization | China National Pharmaceutical Group

China National Pharmaceutical Group Report issue

For profit Phase 2 Phase 3 Phase 4

Founded: Beijing China (1998)

Organization Overview

First Clinical Trial

2020

NCT04456595

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Sinopharm Tongmei(datong) healthcare corporation | Sinovac Life Sciences Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

inactivated covid-19 vaccine (3 trials)

Drugs in Phase 3 Trials (3)

inactivated SARS-Cov-2 vaccine (2 trials)

tetanus toxoid (1 trial)

trivalent covid-19 vaccine (vero cell), inactivated, prototype strain, delta strain and omicron strain (2 trials)

Drugs in Phase 2 Trials (3)

bibp omicron inactivated covid-19 vaccine (vero cell) (1 trial)

coronavac (1 trial)

sa55 (3 trials)

Drugs in Other Trials (3)

midazolam (versed) (1 trial)

remimazolam (Byfavo) (1 trial)

sa58 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Infections (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 13
# of Trial APIs: 10